News
TVGN
1.450
+12.40%
0.160
Weekly Report: what happened at TVGN last week (1230-0103)?
Weekly Report · 5d ago
Weekly Report: what happened at TVGN last week (1223-1227)?
Weekly Report · 12/30/2024 10:43
Tevogen Bio to Host Panel Discussions “AI In Biopharma: Next Frontier of Medical Innovation” and “Pioneering the Economics of Health: Balancing Access and Outcomes” During J.P. Morgan Healthcare Conference
Barchart · 12/26/2024 11:21
Weekly Report: what happened at TVGN last week (1216-1220)?
Weekly Report · 12/23/2024 10:49
Tevogen Bio to Host Panel "AI In Biopharma: Next Frontier of Medical Innovation" During the 43rd Annual J.P. Morgan Healthcare Conference
Barchart · 12/23/2024 08:38
Tevogen Bio Files Additional Patent to Advance AI Initiatives in Immunotherapy Development
Barchart · 12/19/2024 17:56
Tevogen files for additional patent on predictive AI
TipRanks · 12/19/2024 13:50
Tevogen Bio Strengthens Robust IP Portfolio With Filing of Predictive AI Patent, With the Goal to Establish a Blueprint to Unlock the Full Potential of T Cell Therapies and Accelerate AI Integration to Advance Its Bold Growth Agenda
Barchart · 12/19/2024 07:30
Tevogen Bio Holdings Inc.: Excessive Insider Ownership And Poised For A Seasonal Rebound
Seeking Alpha · 12/18/2024 07:29
Tevogen Bio to Host Panel “Pioneering the Economics of Health: Balancing Access and Outcomes” During the 43rd Annual J.P. Morgan Healthcare Conference
Barchart · 12/17/2024 12:32
Tevogen Bio Claims $10 Billion IP Potential But Hinges On Monetization
Seeking Alpha · 12/16/2024 21:58
Weekly Report: what happened at TVGN last week (1209-1213)?
Weekly Report · 12/16/2024 10:49
Tevogen Bio to Attend the 43rd Annual J.P. Morgan Healthcare Conference
Barchart · 12/10/2024 14:13
Weekly Report: what happened at TVGN last week (1202-1206)?
Weekly Report · 12/09/2024 10:48
Dr. Ryan Saadi Commends Individuals Who Dedicate Time to Public Service, and Congratulates Mayor Victor Sordillo on His Induction Into the NJ League of Municipalities Hall of Fame
Barchart · 12/05/2024 10:03
Weekly Report: what happened at TVGN last week (1125-1129)?
Weekly Report · 12/02/2024 10:48
Tevogen Bio Expands Leadership Roles to Enhance Company Capabilities and Growth Strategy
Barchart · 11/26/2024 17:20
Tevogen announces additional responsibilities for key leaders
TipRanks · 11/26/2024 13:15
Tevogen Bio Prepares Organizational Readiness to Support Company’s Growth Strategy
Barchart · 11/26/2024 07:05
Weekly Report: what happened at TVGN last week (1118-1122)?
Weekly Report · 11/25/2024 10:42
More
Webull provides a variety of real-time TVGN stock news. You can receive the latest news about Tevogen Bio through multiple platforms. This information may help you make smarter investment decisions.
About TVGN
Tevogen Bio Holdings Inc. is a clinical-stage specialty immunotherapy company. The Company is harnessing CD8+ cytotoxic T lymphocytes (CD8+ CTLs), to develop off-the-shelf, genetically unmodified precision T cell therapies for the treatment of infectious diseases, cancers, and neurological disorders, aiming to address the unmet needs of patient populations. Its first product candidate, TVGN 489, is an off-the-shelf, allogeneic cytotoxic CD8+ T cell therapy designed to fill a critical gap in COVID-19 therapeutic solutions for the immunocompromised and the high-risk elderly, with potential applications in both treatment and prevention of Long COVID. In addition to TVGN 489, it has several product candidates under early-stage development. The Company is developing Epstein-Barr virus (EBV) specific CTLs for potential use in multiple sclerosis (MS) and EBV-associated lymphomas. Its TVGN 601 is being developed for MS, and its TVGN 930 is being developed for EBV-associated lymphomas.